The frequency of hypertension in patients with pathological obesity

Abstract

Obesity and hypertension are one of the most important cardiovascular risk factors. It is predicted that by 2030 almost two-thirds of the global population will struggle with being overweight or obese. Ambulatory Blood Pressure Measurement (ABPM) is a tool for a detailed analysis of mean blood pressure values and assessing the blood pressure profile during the night with the daily values and optimal treatment determination.The study aimed to assess the frequency of hypertension in patients with pathological obesity.The study consisted of two groups depending on their Body Mass Index (BMI): Group 1 BMI > 25 kg/m 2 ; < 40 kg/m 2 ; Group 2 (243 overweight and obese patients): BMI ≥ 40 kg/m 2 . Each patient was carefully interviewed, considering their use of the antihypertensive drugs. Each patient was subject to the ABPM assessment. Arterial hypertension (HT) was diagnosed at arterial blood pressure (BP) values > 135/85 mmHg based on the European Society of Hypertension (ESH) test bench. Depending on the patient's history, ABPM, and in-office BP measurements, patients were diagnosed with HT treated, newly diagnosed, or without HT. Based on the in-office BP and ABPM measurements taken, the diagnosis of white-coat uncontrolled hypertension (WUCH) and masked uncontrolled hypertension (MUCH) was diagnosed.The analysis of parameters revealed that all BP values were significantly higher in group 2. More than half of the patients in both groups had been previously treated for HT. Based on ABPM, newly diagnosed HT was identified significantly more often in patients with higher BMI. The younger individuals were significantly more likely to have WUCH.

Semaglutide as a chance for obesity treatment

“…The prevalence of obesity has more than doubled in over 70 countries since 1980, and this upward trend is evident across the globe [1]. Furthermore, approximately 2 billion adults are estimated to be overweight, thus being at risk of becoming obese [2]. Obesity has been linked to a multitude of coexisting disease entities, which have a major influence on mortality rates and overall quality of life.…”

The functioning in chronic illness –— a key determinant of treatment efficacy in patients with metabolic syndrome

“…Metabolic syndrome (MetS) including obesity, hypertension, impaired glucose metabolism, and elevated non-high-density lipoprotein cholesterol level due to increasing prevalence and serious impact on clinical outcomes constitutes a significant health and social problem [1]. Recently several papers published in "Medical Research Journal" presented different therapeutic approaches in this subset of patients [2][3][4][5][6].…”